Cardinal Health: Q3 Miss, Buybacks, Guidance Lift!

Cardinal Health (NYSE: CAH) delivered a mixed fiscal third quarter that combined a top-line miss and a one-time goodwill impairment with stronger non-GAAP earnings, an improved full-year outlook, and continued shareholder capital returns. Investors parsed the numbers and management actions, sending the stock lower on the day despite positive signals about earnings power and capital allocation.

Headline results: revenue miss and impairment

For Q3 FY2026, Cardinal Health reported revenue of $60.94 billion, falling short of consensus expectations. The quarter included a $184 million pre-tax goodwill impairment tied to its Navista and Integrated Oncology Network reporting units. That charge weighed on GAAP results: GAAP operating earnings declined roughly 30% year-over-year and GAAP EPS fell to $1.69.

Why the impairment matters

The goodwill write-down highlights integration challenges in specialty services acquired over recent years. While impairments are non-cash and reflect prior acquisition accounting, they can signal that certain assumptions about synergies or growth didn’t materialize as expected. For investors focused on recurring cash generation, the impairment is an important caveat when comparing GAAP and adjusted results.

Adjusted performance and guidance

Cardinal’s adjusted metrics painted a brighter picture: non-GAAP operating earnings increased and non-GAAP EPS rose to $3.17, a meaningful improvement year-over-year. Management tightened and raised its FY2026 non-GAAP EPS guidance to a range of $10.70–$10.80, indicating confidence in core operating performance despite the one-time charge.

Capital allocation: buybacks and dividends

Alongside the guidance raise, Cardinal completed an additional $250 million share repurchase and maintained its quarterly dividend. These actions underscore management’s intent to return capital to shareholders and support per-share metrics, even while navigating top-line pressures. For yield-focused and valuation-oriented investors, steady dividends plus buybacks help offset concerns raised by the revenue miss.

Market reaction and analyst posture

Investors reacted sharply to the mixed print: shares fell approximately 7.8% on the earnings release, reflecting disappointment over the revenue shortfall and the impairment. Despite the pullback, several analysts remained constructive. Notable activity included JPMorgan lifting its price target to $215 and Evercore ISI reaffirming a Buy rating—signals that Wall Street still sees medium-term upside tied to specialty services growth and operational improvements.

Institutional moves and investor sentiment

Recent SEC filings show mixed institutional flows in early May, with some funds adjusting positions. The combination of a buyback, stable dividend, and raised adjusted guidance likely reduces downside risk for some holders while introducing near-term volatility driven by headline GAAP results.

Conclusion

Cardinal Health’s latest quarter is a study in contrasts: a revenue miss and a material goodwill impairment that pressured GAAP results, versus stronger non-GAAP earnings, a tightened FY2026 guidance range, and active capital returns. The issuance of a buyback and continued dividend supports shareholder value, while analyst upgrades suggest confidence that specialty and operational initiatives can drive recovery. Investors should weigh the one-time accounting charges against the company’s core cash generation and strategic direction when assessing CAH’s outlook and valuation.